Cargando…

Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia

BACKGROUND: Little data exists predicting the resistance to actinomycin D (Act-D) single-agent for gestational trophoblastic neoplasia (GTN). The objective was to determine the overall success of pulse Act-D and the factors predictive of resistance to pulse Act-D in the treatment of low-risk, non-ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lei, Wan, Xirun, Feng, Fengzhi, Ren, Tong, Yang, Junjun, Zhao, Jun, Jiang, Fang, Xiang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966914/
https://www.ncbi.nlm.nih.gov/pubmed/29792175
http://dx.doi.org/10.1186/s12885-018-4512-5
_version_ 1783325534661378048
author Li, Lei
Wan, Xirun
Feng, Fengzhi
Ren, Tong
Yang, Junjun
Zhao, Jun
Jiang, Fang
Xiang, Yang
author_facet Li, Lei
Wan, Xirun
Feng, Fengzhi
Ren, Tong
Yang, Junjun
Zhao, Jun
Jiang, Fang
Xiang, Yang
author_sort Li, Lei
collection PubMed
description BACKGROUND: Little data exists predicting the resistance to actinomycin D (Act-D) single-agent for gestational trophoblastic neoplasia (GTN). The objective was to determine the overall success of pulse Act-D and the factors predictive of resistance to pulse Act-D in the treatment of low-risk, non-choriocarcinoma post-molar GTN. METHODS: From January 2013 to October 2016, according to the FIGO criteria for the diagnosis of post-molar disease and the FIGO risk-factor scoring system for GTN, a total of 135 patients with post-molar non-choriocarcinoma GTN who were chemotherapy-naive with a FIGO score < 7 were treated with single-agent pulse Act-D as a first-line regimen, in Peking Union Medical College Hospital. The pulse Act-D regimen is defined as 1.25 mg/m(2) (max 2 mg) IV push every other week. All patients were followed until May 2017. Epidemiological and clinical data were compared between patients with remission and resistance to Act-D to determine predictive factors by univariate and multivariate analysis. RESULTS: Ninety-six of 135 patients (71.1%) achieved complete remission after first-line chemotherapy of pulse Act-D. In multivariate analysis, existing invasive uterine lesions observed by pre-chemotherapy transvaginal ultrasound (odds ratio [OR] 7.5, 95% confidence intervals [CI] 2.7–20.8), FIGO score ≥ 5 (OR 15.2, 95% CI 1.5–156.1) and pre-chemotherapy levels of β-hCG ≥ 4000 IU/L (OR 3.1, 95% CI 1.2–8.3) were independent high-risk factors predicting resistance to pulse Act-D as single-agent chemotherapy. During follow-up, no relapse, treatment-associated serious adverse events, or death occurred. CONCLUSIONS: As first-line chemotherapy, pulse Act-D was effective and tolerable for patients with low-risk post-molar non-choriocarcinoma. Existing invasive uterine lesions observed by pre-chemotherapy transvaginal ultrasound, a FIGO score ≥ 5, and pre-chemotherapy levels of β-hCG ≥ 4000 IU/L were independent factors for resistance to pulse Act-D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4512-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5966914
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59669142018-05-24 Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia Li, Lei Wan, Xirun Feng, Fengzhi Ren, Tong Yang, Junjun Zhao, Jun Jiang, Fang Xiang, Yang BMC Cancer Research Article BACKGROUND: Little data exists predicting the resistance to actinomycin D (Act-D) single-agent for gestational trophoblastic neoplasia (GTN). The objective was to determine the overall success of pulse Act-D and the factors predictive of resistance to pulse Act-D in the treatment of low-risk, non-choriocarcinoma post-molar GTN. METHODS: From January 2013 to October 2016, according to the FIGO criteria for the diagnosis of post-molar disease and the FIGO risk-factor scoring system for GTN, a total of 135 patients with post-molar non-choriocarcinoma GTN who were chemotherapy-naive with a FIGO score < 7 were treated with single-agent pulse Act-D as a first-line regimen, in Peking Union Medical College Hospital. The pulse Act-D regimen is defined as 1.25 mg/m(2) (max 2 mg) IV push every other week. All patients were followed until May 2017. Epidemiological and clinical data were compared between patients with remission and resistance to Act-D to determine predictive factors by univariate and multivariate analysis. RESULTS: Ninety-six of 135 patients (71.1%) achieved complete remission after first-line chemotherapy of pulse Act-D. In multivariate analysis, existing invasive uterine lesions observed by pre-chemotherapy transvaginal ultrasound (odds ratio [OR] 7.5, 95% confidence intervals [CI] 2.7–20.8), FIGO score ≥ 5 (OR 15.2, 95% CI 1.5–156.1) and pre-chemotherapy levels of β-hCG ≥ 4000 IU/L (OR 3.1, 95% CI 1.2–8.3) were independent high-risk factors predicting resistance to pulse Act-D as single-agent chemotherapy. During follow-up, no relapse, treatment-associated serious adverse events, or death occurred. CONCLUSIONS: As first-line chemotherapy, pulse Act-D was effective and tolerable for patients with low-risk post-molar non-choriocarcinoma. Existing invasive uterine lesions observed by pre-chemotherapy transvaginal ultrasound, a FIGO score ≥ 5, and pre-chemotherapy levels of β-hCG ≥ 4000 IU/L were independent factors for resistance to pulse Act-D. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4512-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-23 /pmc/articles/PMC5966914/ /pubmed/29792175 http://dx.doi.org/10.1186/s12885-018-4512-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Lei
Wan, Xirun
Feng, Fengzhi
Ren, Tong
Yang, Junjun
Zhao, Jun
Jiang, Fang
Xiang, Yang
Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title_full Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title_fullStr Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title_full_unstemmed Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title_short Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
title_sort pulse actinomycin d as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966914/
https://www.ncbi.nlm.nih.gov/pubmed/29792175
http://dx.doi.org/10.1186/s12885-018-4512-5
work_keys_str_mv AT lilei pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT wanxirun pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT fengfengzhi pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT rentong pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT yangjunjun pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT zhaojun pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT jiangfang pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia
AT xiangyang pulseactinomycindasfirstlinetreatmentoflowriskpostmolarnonchoriocarcinomagestationaltrophoblasticneoplasia